Ripping Theodora Maria, Hubbard Rebecca A, Otten Johannes D M, den Heeten Gerard J, Verbeek André L M, Broeders Mireille J M
Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands.
Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA.
Int J Cancer. 2016 Apr 1;138(7):1619-25. doi: 10.1002/ijc.29912. Epub 2015 Nov 20.
Several reviews have estimated the balance of benefits and harms of mammographic screening in the general population. The balance may, however, differ between individuals with and without family history. Therefore, our aim is to assess the cumulative risk of screening outcomes; screen-detected breast cancer, interval cancer, and false-positive results, in women screenees aged 50-75 and 40-75, with and without a first-degree relative with a history of breast cancer at the start of screening. Data on screening attendance, recall and breast cancer detection were collected for each woman living in Nijmegen (The Netherlands) since 1975. We used a discrete time survival model to calculate the cumulative probability of each major screening outcome over 19 screening rounds. Women with a family history of breast cancer had a higher risk of all screening outcomes. For women screened from age 50-75, the cumulative risk of screen-detected breast cancer, interval cancer and false-positive results were 9.0, 4.4 and 11.1% for women with a family history and 6.3, 2.7 and 7.3% for women without a family history, respectively. The results for women 40-75 followed the same pattern for women screened 50-75 for cancer outcomes, but were almost doubled for false-positive results. To conclude, women with a first-degree relative with a history of breast cancer are more likely to experience benefits and harms of screening than women without a family history. To complete the balance and provide risk-based screening recommendations, the breast cancer mortality reduction and overdiagnosis should be estimated for family history subgroups.
已有多项综述评估了普通人群中乳腺钼靶筛查的利弊平衡。然而,有家族病史和无家族病史的个体之间的利弊平衡可能存在差异。因此,我们的目的是评估筛查结果的累积风险;在筛查开始时,对年龄在50 - 75岁和40 - 75岁、有和没有乳腺癌家族史的女性筛查对象进行筛查发现的乳腺癌、间期癌和假阳性结果。自1975年以来,收集了居住在荷兰奈梅亨的每位女性的筛查出勤、召回和乳腺癌检测数据。我们使用离散时间生存模型来计算19轮筛查中每个主要筛查结果的累积概率。有乳腺癌家族史的女性出现所有筛查结果的风险更高。对于年龄在50 - 75岁接受筛查的女性,有家族史的女性筛查发现乳腺癌、间期癌和假阳性结果的累积风险分别为9.0%、4.4%和11.1%,无家族史的女性分别为6.3%、2.7%和7.3%。40 - 75岁女性的结果在癌症结果方面与50 - 75岁接受筛查的女性遵循相同模式,但假阳性结果几乎翻倍。总之,有乳腺癌家族史的女性比无家族史的女性更有可能经历筛查的益处和危害。为了完善利弊平衡并提供基于风险的筛查建议,应估计家族史亚组的乳腺癌死亡率降低情况和过度诊断情况。